2 biotech stocks that could boom as potential Big Pharma acquisition targets

Upfront pharma M&A in the first four months of 2026 reached $64 billion across 24 deals, versus $24.5 billion across 14 deals in the same window of 2025.1 The two specialty biotechs that match the buyers' actual pattern are hiding in plain sight.